

Making the DARPin[®] Difference Reality for Patients

Patrick Amstutz, CEO

Andreas Emmenegger, CFO

Fireside Chat at Morgan Stanley Global Healthcare Conference, New York

Molecular Partners AG, Switzerland (SIX: MOLN) - September 12, 2018

Molecular Partners: Who We Are



Teamwork

- Swiss biotech (SIX: MOLN)
- **120 team members**
- Discovery to Phase 2 (POC)
- Science & patients first



DARPin® Therapies

- **Abicipar** in Phase 3 (ophtha)
- MP0250 in Phase 2 (onc)
- MP0274 in Phase 1 (onc)
- Broad preclin. I/O portfolio



Partnerships

- Alliance with Allergan
- **Agreement with AstraZeneca**
- **Cash CHF 122m (H1 2018)**
- Financed well beyond key value inflection points





DARPin® Engine

- DARPin® Difference: test novel therapeutic design
- Proof of DARPin® candidates in eye and systemically
- Fast and cost effective drug discovery engine


DARPin® Proteins: Beyond Target Space of Antibodies

MONOCLONAL ANTIBODIES

Binding regions / specificity





- High affinity and specificity
- Large size: 150 kDa
- Complex architecture: 4 proteins with 12 domains
- Target binding via flexible surface loops (CDRs)
- Long half-life



DARPin® Protein(s)

DARPin® module

Binding region / specificity



Opportunity to explore **unique architectures** to test novel **therapeutic designs**


Multi-DARPin® product candidate

- High affinity and specificity
- Small size: 15 kDa (1/10 of monoclonal antibody)
- Simple architecture: 1 protein with 1 domain
- Target binding via rigid surface structure
- Tunable half-life

Modular Approach to Customized Drug Candidates

Building blocks

DARPin® modules



Peptide linkers: Short, long, flexible, rigid




Non-DARPin® element (chemical, toxin or other proteins)




Candidates


Multi-DARPin® product candidate (e.g. MP0250, MP0274)



High flexibility permits binding with complex geometries




DARPin® module conjugated to non-DARPin® element




DARPin® Engine: Rapid Screening and Discovery, Flexible Design, Tailored to Therapeutic Need


DARPin® module selection




Screening multi-DARPin® space of up to 10,000 functional combinations



Identifying novel therapeutic designs




Pipeline: A Balanced and Robust Portfolio



AMD: age-related macular degeneration; DME: diabetic macular edema; NSCLC: non-small cell lung cancer

Ready to Capture Value Beyond Ophthalmology



Illustrative only

Investment Case and Key Messages

- Successful transition from DARPin[®] platform into **clinical oncology company**:
 - **MP0250** (Phase 2) demonstrated initial activity in MM and is progressing in NSCLC (EGFR-mut)
 - MP0274 (Phase 1) ongoing in Her2+ cancers
 - MP0310 selected as 1st development candidate (preclinical) from **I/O DARPin[®] toolbox**
- **Abicipar** Phase 3 in nAMD progressing with partner Allergan:
 - Top-line data demonstrated **non-inferiority of abicipar Q12 vs Lucentis Q4 dosing**
 - Further optimized formulation is being tested to reduce inflammation (MAPLE trial)
- Financed into 2020 (excluding any abicipar-related proceeds), capturing key value inflection points
- Keep on forward integrating towards late-stage development and the market

DARPin[®] is a registered trademark owned by Molecular Partners AG.

Multiple Value Inflection Points Ahead

	2018	2019	2020
Abicipar	nAMD: 1-y Ph 3 efficacy 	Data from further optimized formulation (MAPLE trial) H1/19 FDA filing planned for H1/19 DME: Ph 3 expected start	nAMD: expected launch
MP0250	MM: initial efficacy NSCLC: initial safety	MM: efficacy NSCLC: initial efficacy	NSCLC: efficacy
MP0274	Initial safety	Initial efficacy	
MP0310	Preclinical data	FIH	
Funding into 2020 (excl. any abicipar related proceeds)			

Appendix



Experienced Management Team & Board of Directors

Executive Management



Dr. Patrick Amstutz, CEO

- Co-founder, former CBO & COO
- **Member of the Board of Directors**
- PhD in molecular biology from UZH



Dr. Andreas Harstrick, CMO, MD

- 30 years of experience in oncology
- Developed multiple mAb oncology products
- Senior positions at Merck-Serono, Imclone, Eli Lilly



Dr. Michael Stumpp, COO

- Co-founder
- PhD and postdoc from UZH; research in Tokyo, London



Andreas Emmenegger, CFO

- Former CFO Glycart, Finance Roles at Roche
- >20 years experience as CFO of private & listed companies and in fund raising, IPOs



Dr. Pamela Trail, CSO

- >30 years of experience in directing cancer drug discovery at leading global pharma companies

Board of Directors



Bill Burns, Chairman

- Former CEO of Roche Pharmaceuticals
- Former board member of Roche, Genentech, Chugai Pharmaceuticals, Shire



Göran Ando, Vice Chairman

- Former Chairman, Novo Nordisk
- Former CSO, Pharmacia



Gwen Fyfe

- Former VP, Oncology Development at Genentech



Steven H. Holtzman

- President and CEO, Decibel Therapeutics
- Former EVP, Biogen



William "Bill" Lee

- EVP Research, Gilead




Petri Vainio

- Managing Director, Essex Woodlands Ventures

Shareholder Structure

Shareholder structure as of June 30, 2018



- Pre-IPO investors (4 VC's)
- Management, Board, Founders
- Others

Highlights

- VC holdings halved vs. end 2016 to 23%
- Listed on SIX Swiss Exchange (SIX: MOLN)
- Included in key indices: SPI, SPI Extra, SXI Life Sciences and SXI Bio+Medtech
- 21,180,138 shares outstanding
- Ca. CHF 486 million market cap. as of June 30, 2018
- No lock-up restrictions in place
- Formal free float as per SIX definition: 84%

IR Agenda

<i>Date</i>	<i>Event</i>
November 1, 2018	Q3 2018 Management Statement
December 6, 2018	R&D Day in New York
February 7, 2019	Publication of Full-year Results 2018 (unaudited)
March 15, 2019	Expected Publication of Annual Report 2018
April 16, 2019	Annual General Meeting

Disclaimer

This presentation is not an offer to sell or a solicitation of offers to purchase or subscribe for shares of Molecular Partners AG, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision. This presentation is not an offering circular within the meaning of Article 652a of the Swiss Code of Obligations, nor is it a listing prospectus as defined in the listing rules of the SIX Swiss Exchange AG or a prospectus under any other applicable laws. Copies of this presentation may not be sent to countries, or distributed in or sent from countries, in which this is barred or prohibited by law. This document is not a prospectus or a prospectus equivalent document and investors should not subscribe for or purchase any securities referred to in this document. This document does not constitute a recommendation regarding the shares.

This presentation contains specific forward-looking statements, beliefs or opinions, including statements with respect to the product pipelines, potential benefits of product candidates and objectives, estimated market sizes and opportunities as well as the milestone potential under existing collaboration agreements, which are based on current beliefs, expectations and projections about future events, e.g. statements including terms like “potential”, “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Molecular Partners AG and investments and those explicitly or implicitly presumed in these statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these statements and forecasts. Past performance of Molecular Partners AG cannot be relied on as a guide to future performance. Forward-looking statements speak only as of the date of this presentation and Molecular Partners AG, its directors, officers, employees, agents, counsel and advisers expressly disclaim any obligations or undertaking to release any update of, or revisions to, any forward looking statements in this presentation. No statement in this document or any related materials or given at this presentation is intended as a profit forecast or a profit estimate and no statement in this document or any related materials or given at this presentation should be interpreted to mean that earnings per share for the current or future financial periods would necessarily match or exceed historical published earnings per share. As a result, you are cautioned not to place any undue reliance on such forward-looking statements.

Unless stated otherwise the information provided in this presentation are based on company information. This presentation is intended to provide a general overview of Molecular Partners AG’s business and does not purport to deal with all aspects and details regarding Molecular Partners AG. Accordingly, neither Molecular Partners AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to, and accordingly no reliance should be placed on, the accuracy or completeness of the information contained in the presentation or of the views given or implied. Neither Molecular Partners AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person shall have any liability whatsoever for any errors or omissions or any loss howsoever arising, directly or indirectly, from any use of this information or its contents or otherwise arising in connection therewith.

The material contained in this presentation reflects current legislation and the business and financial affairs of Molecular Partners AG which are subject to change and audit.

Molecular Partners AG

Wagistrasse 14

8952 Zürich-Schlieren

Switzerland

www.molecularpartners.com

T +41 44 755 77 00

